In yesterday’s Wall Street session, Opko Health Inc (NASDAQ:OPK) shares traded at $1.22, down -0.81% from the previous session.
OPK stock price is now 12.24% away from the 50-day moving average and -12.72% away from the 200-day moving average. The market capitalization of the company currently stands at $850.33M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $2, Barrington Research recently Upgraded its rating from Mkt Perform to Outperform for Opko Health Inc (NASDAQ: OPK). On December 15, 2022, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $3, while ‘Barrington Research’ rates the stock as ‘Mkt Perform’
In other news, FROST PHILLIP MD ET AL, CEO & Chairman bought 500,000 shares of the company’s stock on Mar 18 ’24. The stock was bought for $437,100 at an average price of $0.87. Upon completion of the transaction, the CEO & Chairman now directly owns 210,968,225 shares in the company, valued at $257.38 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 14 ’24, CEO & Chairman FROST PHILLIP MD ET AL bought 500,000 shares of the business’s stock. A total of $444,300 was incurred on buying the stock at an average price of $0.89. This leaves the insider owning 210,468,225 shares of the company worth $256.77 million. A total of 52.98% of the company’s stock is owned by insiders.
During the past 12 months, Opko Health Inc has had a low of $0.85 and a high of $2.24. As of last week, the company has a debt-to-equity ratio of 0.24, a current ratio of 1.55, and a quick ratio of 1.22.
According to the Diagnostics & Research Company, earnings per share came in at -0.02, beating analysts’ expectations of -0.08 by 0.06. This compares to -$0.12 EPS in the same period last year. The net profit margin was -21.87% and return on equity was -12.80% for OPK. The company reported revenue of $181.91 million for the quarter, compared to $185.34 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.85 percent. For the current quarter, analysts expect OPK to generate $182.99M in revenue.
